Creative Biolabs has over a decade of working experience in Anti-Virus Biomolecular Discovery. Based on our advanced AntInfect™ Platform, our seasoned scientists can offer high-quality Zika virus (ZIKV) neutralizing antibody and ZIKV-specific peptide discovery services.
https://www.creative-biolabs.com/antinfect/discovery-of-neutralizing-antibody-nab-and-peptide-targeting-zika-virus.htm
1. The leading custom service provider in antibody development and engineering
Anti-Virus Biomolecular
Discovery
To Discovery Best-in-class Biomolecular Therapies for Infective Diseases
Web: www.creative-biolabs.com
Email: info@creative-biolabs.com
Address: 203, 17 Ramsey Road, Shirley, NY 11967, USA
2. 1. Virus of Infectious Diseases
2. Viral Pathogenesis
3. Our Platform
4. Main Technologies
CONTENTS
9. Introduction to Viral Pathogenesis
2 Viral Pathogenesis
Loss of cell function
Kill cells
Tissue damage caused by host immune responses
Complex combination of direct damage & host
immune responses
10. Routes of Virus Entry
2 Viral Pathogenesis
Entry via the Respiratory Tract
Entry via the Gastrointestinal Tract
Entry via the Skin
Entry via Other Routes
Image From Fenner’s Veterinary Virology. DOI:10.1016/B978-0-12-375158-4.00003-1
11. 2 Viral Pathogenesis
Neural spread
Hematogenous Spread
Local Spread on Epithelial Surfaces
Subepithelial Invasion and Lymphatic Spread
Mechanisms of Viral Spread and Infection
12. Mechanisms of Virus Shedding
2 Viral Pathogenesis
Via budding
Via apoptosis
Via exocytosis
Image From Fenner’s Veterinary Virology. DOI:10.1016/B978-0-12-375158-4.00003-1 Image From Wikipedia
13. Virus Transmission
2 Viral Pathogenesis
Fecal-oral Respiratory Droplets Fomites-mediated
Exchange of Bodily
Fluids or Organs
Airborne Insect Vectors
14. Mechanisms of Viral Injury and Disease
2 Viral Pathogenesis
Image From Fenner’s Veterinary Virology. DOI:10.1016/B978-0-12-375158-4.00003-1
Inhibition of Host-Cell Nucleic Acid
Synthesis
Inhibition of Host-Cell RNA
Transcription
Inhibition of Processing of Host-Cell
Messenger RNAs
Inhibition of Host-Cell Protein
Synthesis
15. Neutralizing Antibody Targets of Viral Disease
2 Viral Pathogenesis
Take AIDS as an example
CD4 binding site (CD4bs) V2 site
Membrane proximal external
region (MPER)
N332 supersite
Gp120–gp41 interface
17. Antibodies directed against membrane proteins for neutralization of virus infectivity are highly sought for
therapeutic, diagnostic, and research purposes. Creative Biolabs has developed a series of cell-based systems and
cell-free systems for virus membrane protein expression.
Membrane Protein Production and Immunization Platform
Creative Biolabs has established a broad range of expression systems including but not
limited to E. coli system, yeast system, insect system, plant system, mammalian system.
We have accumulated extensive experience in anti-virus antibody development by using
VLP immunization strategy.
VLPs Production and Immunization Platform
Creative Biolabs can offer a series of DNA immunization
strategies to develop high-affinity antibodies against the
natural conformation of the target antigen.
DNA Immunization Platform
Anti-Virus Biomolecular Discovery
3 Our Platform
18. Ph.D. level scientists with
extensive experience
Cost-effective and short turnaround
Board-spectrum targets
Various strategies
Diverse species available
High-throughput functional molecules
screening
Large pool of functional
antibody/peptide candidates
AntInfect™ Platform
3 Our Platform
20. Antigen-Specific B Lymphocytes Sorting Technology
Fluorescent activated cell sorting (FACS) Laser-capture Microdissection (LCM)
4 Main Technologies
21. Generation of Monoclonal Antibodies
Hybridoma Technology
Abdullah Farhan ul haque Saeed, et al. Antibody Engineering for Pursuing a Healthier Future. Front Microbiol. 2017, 8,
495. doi:10.3389/fmicb.2017.00495
4 Main Technologies
23. High-Density Peptide Array
Michael Hecker, et al. High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of
Multiple Sclerosis Patients. Molecular & Cellular Proteomics. 2016,15(4): 1360-1380.
4 Main Technologies